ADDUS HOMECARE CORP

Company Overview

Addus HomeCare Corp (ADUS) is a Texas‑based provider of home health, hospice and personal care services operating in the Healthcare sector, industry classified as Medical Care Facilities / Home Health Care Services. Q2 2025 results show rapid top‑line expansion (net service revenues $349.4M, +21.8% Y/Y) driven largely by the Dec. 2, 2024 Gentiva acquisition and organic hospice growth, while home health was essentially flat. Personal care scale expanded materially (average billable census ~50.4k vs 38.0k Y/Y) but revenues per billable hour declined (~7.2%) due to acquired reimbursement mix and a New York divestiture. Key operational and financial constraints include payor concentration (Illinois ~18.6% of revenue), wage and recruiting pressures, DSO ~38 days, and exposure to state/CMS reimbursement changes and potential federal cuts.

Executive Compensation Practices

Given the acquisition‑led growth profile and margin sensitivity, management compensation is likely to emphasize integration and M&A execution, revenue and billable census growth (particularly in personal care and hospice), along with margin and cash‑flow targets (DSO, operating cash, and leverage). The recent Gentiva deal and higher administrative costs suggest retention awards, sign‑on or transition bonuses, and short‑term cash incentives tied to successful integration milestones are probable, while long‑term equity (PSUs/options) would typically be used to align executives to multi‑year EBITDA, adjusted net income and total shareholder return. Because leverage, interest expense and a 3.75x net leverage covenant are meaningful, incentive plans may include covenant‑compliance or deleveraging metrics and clawback/vesting‑forfeiture provisions tied to regulatory or reimbursement reversals. Industry norms in Healthcare / Home Health Care Services — base salary + annual cash bonus + multi‑year equity grants — likely apply, with added retention features due to labor market pressure.

Insider Trading Considerations

Insiders at Addus will frequently possess material nonpublic information tied to acquisitions, state reimbursement rate decisions (e.g., Illinois, Texas), CMS rule changes (HHVBP, Medicaid 80/20 guidance) and covenant/leverage status, so trading windows and blackout periods around earnings, major regulatory news, and M&A milestones are particularly important. Expect clustered insider activity following public earnings or announced transactions (Gentiva acquisition, NY asset sale) and potential opportunistic selling after equity vesting or to cover tax/liquidity needs from acquisition‑related awards. Given the regulatory and payor‑concentration risks, observers should watch for 10b5‑1 plan usage, large sales shortly before or after reimbursement announcements, and disclosures tied to covenant tests or revolver drawdowns; such patterns can be especially informative for traders and researchers monitoring event risk in this sector.